1048 GMT - AstraZeneca stands out among peers with its diversified pipeline of new experimental drugs and extensions for on-market assets, UBS analysts say in a note. "Clearly some studies will fail, but 2025 is a key catalyst year with data on seven high-value new drugs," they say. Its new small-cell lung and bladder indications for cancer drug Imfinzi and its late stage trials to broaden the label of pulmonary disease treatment Breztri are promising, they say. UBS analysts estimate that the British pharma company's late-stage pipeline has potential to add a further $17.6 billion sales in 2030. UBS upgrades its rating on the stock to buy from neutral. Shares are up 1.7% at 120.00 pounds. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
February 13, 2025 05:49 ET (10:49 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.